DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Abemaciclib and Letrozole to Treat Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Abemaciclib
Drug: Letrozole

First Posted Date: 2020-05-19

Last Posted Date: 2023-12-13

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 53

Registration Number: NCT04393285

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Miami - Sylvester Cancer Center, Miami, Florida, United States

and more 26 locations

Ribociclib and Letrozole Treatment in Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Low Grade Serous Carcinoma

Interventions: Drug: Ribociclib
Drug: Letrozole

First Posted Date: 2018-09-17

Last Posted Date: 2023-02-28

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 51

Registration Number: NCT03673124

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Saint Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States
🇺🇸
The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States

and more 24 locations

Pazopanib for Treating Uterine Leiomyosarcoma

Phase 2

Withdrawn

Conditions: Uterine Leiomyosarcoma

Interventions: Drug: Pazopanib

First Posted Date: 2015-03-04

Last Posted Date: 2015-11-18

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT02378142

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Phase 2

Conditions: Recurrent Uterine Corpus Carcinoma
Endometrial Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IV Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Metformin Hydrochloride
Drug: Paclitaxel
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2014-02-19

Last Posted Date: 2021-09-30

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 469

Registration Number: NCT02065687

Locations: 🇺🇸
Novant Health Cancer Institute - Wilkesboro, Wilkesboro, North Carolina, United States
🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸
AnMed Health Cancer Center, Anderson, South Carolina, United States

and more 428 locations

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Dalantercept
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-11-02

Last Posted Date: 2021-10-20

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 30

Registration Number: NCT01720173

Locations: 🇺🇸
Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States
🇺🇸
The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States
🇺🇸
Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States

and more 37 locations

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Mucinous Adenocarcinoma
Endometrial Transitional Cell Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Adenocarcinoma
Endometrial Mixed Adenocarcinoma
Endometrial Squamous Cell Carcinoma
Endometrial Undifferentiated Carcinoma
Recurrent Uterine Corpus Carcinoma

Interventions: Biological: Dalantercept
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-07-17

Last Posted Date: 2018-03-13

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 28

Registration Number: NCT01642082

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Maine Medical Center-Bramhall Campus, Portland, Maine, United States

and more 27 locations

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

Phase 2

Conditions: Stage IIIC Vulvar Cancer AJCC v7
Stage IIIB Vulvar Cancer AJCC v7
Stage IIIA Vulvar Cancer AJCC v7
Stage IVA Vulvar Cancer AJCC v7
Vulvar Squamous Cell Carcinoma
Stage III Vulvar Cancer AJCC v7

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2012-05-09

Last Posted Date: 2021-12-29

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 57

Registration Number: NCT01595061

Locations: 🇺🇸
AdventHealth Hendersonville, Hendersonville, North Carolina, United States
🇺🇸
Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States
🇺🇸
Providence Newberg Medical Center, Newberg, Oregon, United States

and more 190 locations

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Phase 3

Terminated

Conditions: Stage I Uterine Sarcoma AJCC v7
Uterine Corpus Leiomyosarcoma

Interventions: Other: Clinical Observation
Drug: Docetaxel
Drug: Doxorubicin Hydrochloride
Biological: Filgrastim
Drug: Gemcitabine Hydrochloride
Biological: Pegfilgrastim

First Posted Date: 2012-02-15

Last Posted Date: 2020-04-28

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 38

Registration Number: NCT01533207

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States

and more 618 locations

Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection

Conditions: Stage II Vulvar Cancer
Stage III Vulvar Cancer
Vulvar Squamous Cell Carcinoma
Stage I Vulvar Cancer

Interventions: Other: Clinical Observation

First Posted Date: 2011-12-28

Last Posted Date: 2021-09-30

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 148

Registration Number: NCT01500512

Locations: 🇺🇸
University of Arizona Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States
🇺🇸
Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States

and more 34 locations

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Phase 3

Withdrawn

Conditions: Neuropathy
Recurrent Ovarian Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Fatigue
Ovarian Endometrioid Adenocarcinoma
Malignant Ovarian Mixed Epithelial Tumor
Ovarian Clear Cell Cystadenocarcinoma
Pain

Interventions: Dietary Supplement: Acetyl-L-Carnitine Hydrochloride
Other: Placebo
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2011-12-15

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT01492920

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy